Literature DB >> 22245047

Structure-activity relationships for the interaction of 5,10-dihydroindeno[1,2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI.

Deniz Ekinci1, Hüseyin Cavdar, Serdar Durdagi, Oktay Talaz, Murat Sentürk, Claudiu T Supuran.   

Abstract

Several 5,10-dihydroindeno[1,2-b]indole derivatives incorporating methoxy, hydroxyl, and halogen (F, Cl, and Br) moieties on the indene fragment of the molecule were prepared and tested against five carbonic anhydrase (CA, EC 4.2.1.1) isoforms. The inhibitory potencies of these compounds against the human (h) isoforms hCA I, II, IV, VI and bovine (b) isoform bCA III were assessed. Most of them exhibited low micromolar inhibition of these enzymes. K(I) values of these compounds against hCA I and hCA II were in the range of 2.14-16.32 μM, and 0.34-2.52 μM, respectively. Isozyme hCA IV was inhibited with K(I)-s in the range of 0.435-5.726 μM, while hCA VI with K(I)-s of 1.92-12.84 μM bCA III was inhibited with K(I)-s in the range of 2.13-17.83 μM. The structurally related compounds, 1,2-dimethoxybenzene, catechol and indole were also tested in order to understand the structure activity relationship. In silico docking studies of some derivatives within the active site of hCA I and II were also carried out in order to rationalize the inhibitory properties of these compounds and understand their inhibition mechanism. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22245047     DOI: 10.1016/j.ejmech.2011.12.022

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Design, synthesis, in silico and biological evaluation of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazine carboxamides.

Authors:  Shikha Kumari; Chandra Bhushan Mishra; Danish Idrees; Amresh Prakash; Rajesh Yadav; Md Imtaiyaz Hassan; Manisha Tiwari
Journal:  Mol Divers       Date:  2016-12-30       Impact factor: 2.943

Review 2.  Thiazole Ring-A Biologically Active Scaffold.

Authors:  Anthi Petrou; Maria Fesatidou; Athina Geronikaki
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

Review 3.  Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.

Authors:  Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Claudiu T Supuran; Stefano Fais
Journal:  Metabolites       Date:  2017-12-23

4.  Carbonic anhydrase from Apis mellifera: purification and inhibition by pesticides.

Authors:  Ercan Soydan; Ahmet Güler; Selim Bıyık; Murat Şentürk; Claudiu T Supuran; Deniz Ekinci
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

5.  Discovery of Klotho peptide antagonists against Wnt3 and Wnt3a target proteins using combination of protein engineering, protein-protein docking, peptide docking and molecular dynamics simulations.

Authors:  Shaher Bano Mirza; Ramin Ekhteiari Salmas; M Qaiser Fatmi; Serdar Durdagi
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

6.  Inhibition studies on a panel of human carbonic anhydrases with N1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails.

Authors:  Fadi M Awadallah; Silvia Bua; Walaa R Mahmoud; Hossam H Nada; Alessio Nocentini; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

7.  Carbonic anhydrase inhibitory properties of some uracil derivatives.

Authors:  Emir Alper Türkoğlu; Murat Şentürk; Claudiu T Supuran; Deniz Ekinci
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

8.  Design, synthesis and molecular modelling studies of some pyrazole derivatives as carbonic anhydrase inhibitors.

Authors:  Yazgı Dizdaroglu; Canan Albay; Tayfun Arslan; Abdulilah Ece; Emir A Turkoglu; Asiye Efe; Murat Senturk; Claudiu T Supuran; Deniz Ekinci
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.